Normal view MARC view ISBD view

Radioiodine refractory differentiated thyroid cancer. [Review]

MedStar author(s):

Citation: Critical Reviews in Oncology-Hematology. 125:111-120, 2018 May.PMID: 29650270Institution: MedStar Washington Hospital CenterDepartment: Medicine/Nuclear MedicineForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Adenocarcinoma/rt [Radiotherapy] | *Iodine Radioisotopes/tu [Therapeutic Use] | *Neoplasm Recurrence, Local/th [Therapy] | *Thyroid Neoplasms/rt [Radiotherapy] | Adenocarcinoma/dt [Drug Therapy] | Adenocarcinoma/pa [Pathology] | Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use] | Female | Humans | Molecular Targeted Therapy/mt [Methods] | Molecular Targeted Therapy/td [Trends] | Neoplasm Recurrence, Local/dt [Drug Therapy] | Thyroid Neoplasms/dt [Drug Therapy] | Thyroid Neoplasms/pa [Pathology] | Treatment FailureYear: 2018 ISSN:

1040-8428

Name of journal: Critical reviews in oncology/hematologyAbstract: Copyright (c) 2018 Elsevier B.V. All rights reserved.Differentiated thyroid cancer (DTC) is usually curable with surgery, radioactive iodine (RAI), and thyroid-stimulating hormone (TSH) suppression. However, local recurrence and/or distant metastases occur in approximately 15% of cases during follow-up, and nearly two-thirds of these patients will become RAI-refractory (RR-DTC) with a poor prognosis. This review focuses on the most challenging and rapidly evolving aspects of RR-DTC, and we discuss the considerable improvement in more accurately defining RR-DTC, more effective therapeutic strategies, and describe the diagnosis, pathogenesis, and future prospects of RR-DTC. Along with the detection of serum thyroglobulin and anatomic imaging modalities, such as ultrasound and computer tomography, radionuclide molecular imaging plays a vital role in the evaluation of RR-DTC. In addition, continual progress has been made in the management of RR-DTC, including watchful waiting under appropriate TSH suppression, local treatment approaches, and systemic therapies (molecular targeted therapy, redifferentiation therapy, gene therapy, and cancer immunotherapy). These all hold promise to change the natural history of RR-DTC.All authors: Chen L, Cheng L, Jin Y, Liu M, Van Nostrand DFiscal year: FY2018Digital Object Identifier:

https://dx.doi.org/10.1016/j.critrevonc.2018.03.012

Date added to catalog: 2018-06-21

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	29650270	Available		29650270

Differentiated thyroid cancer (DTC) is usually curable with surgery, radioactive iodine (RAI), and thyroid-stimulating hormone (TSH) suppression. However, local recurrence and/or distant metastases occur in approximately 15% of cases during follow-up, and nearly two-thirds of these patients will become RAI-refractory (RR-DTC) with a poor prognosis. This review focuses on the most challenging and rapidly evolving aspects of RR-DTC, and we discuss the considerable improvement in more accurately defining RR-DTC, more effective therapeutic strategies, and describe the diagnosis, pathogenesis, and future prospects of RR-DTC. Along with the detection of serum thyroglobulin and anatomic imaging modalities, such as ultrasound and computer tomography, radionuclide molecular imaging plays a vital role in the evaluation of RR-DTC. In addition, continual progress has been made in the management of RR-DTC, including watchful waiting under appropriate TSH suppression, local treatment approaches, and systemic therapies (molecular targeted therapy, redifferentiation therapy, gene therapy, and cancer immunotherapy). These all hold promise to change the natural history of RR-DTC.

English